Company intelligence / Profile preview

Acrongenomics

Geneva, Geneva, Switzerland

Ownership: Private
Development stage: Other

Overview

Acrongenomics was a biotechnology company focused on the development and commercialization of novel molecular diagnostic technologies. The company specialized in nanotechnology-based platforms, most notably through its licensing and development of Molecular Beacon technology for the detection of genetic sequences. Its primary goal was to provide rapid, highly sensitive, and cost-effective diagnostic tools for applications in oncology and infectious diseases. Despite early promise and public trading, the company faced significant operational challenges and is currently considered inactive.

Therapeutic areas: OncologyInfectious Diseases
Modalities: NanoparticleDiagnostic
Industry: Molecular Diagnostics

Partnerships

Public Health Research Institute

Beyond the preview

Go deeper on Acrongenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acrongenomics.

Explore the full profile